ArticleJugan geon-gang gwa jilbyeong2025
[Characteristics and Trends of Tuberculosis Deaths in 2023: An Analysis of Cause-of-death Statistics from Statistics Korea].
Article in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Performance and Cost-Efficiency of an MPT64 Assay for DetectingJournal of Korean medical science · 2026Article
- Suicide risk in people with tuberculosis in Republic of Korea: a nationwide cohort, 2012-2021.Infectious diseases of poverty · 2026Article
- Comparative tuberculosis risk in healthcare and educational workers: occupational synergy.ERJ open research · 2026Article
- [Review of the Global Burden of Tuberculosis in 2023: Insights from the WHO Global Tuberculosis Report 2024].Jugan geon-gang gwa jilbyeong · 2025Article
- Determinants of the lost to follow-up status among patients with tuberculosis who emigrated to the Republic of Korea: a mixed-method study.Frontiers in public health · 2025Article
- Cohort profile: the KDCA-Tuberculosis-NHIS cohort linking tuberculosis surveillance and health insurance data in Korea.Epidemiology and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is a preventable and curable disease. Republic of Korea has designated TB as a second-class legal infectious disease and has managed patients with TB in the national TB surveillance system. According to Statistics Korea's cause-of-death statistics for October 2024, the number of TB deaths in 2023 was 1,331 (2.6 people per 100,000 population), an increase of 0.7% (n=9) from the previous year (n=1,322, 2.6 people per 100,000 population). The decline in the number of TB deaths appears to have plateaued in 2023, with a slight increase of 0.7% compared to the previous year. Since exceeding 80.0% in 2016, the proportion of total TB deaths among adults aged 65 years and older has accounted for 87.2%. Therefore, the Korea Disease Control and Prevention Agency continues to promote prevention and screening projects for adults aged 65 years and older, and we are implementing a customized TB management project so that patients with TB are managed with medication during the entire TB treatment period from June 2024. We plan to continue to promote strengthened TB policies across the entire TB control cycle (prevention-diagnosis-treatment) to improve the treatment success rate for patients with TB, reduce mortality due to TB, and further accelerate eradication of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.